INVIVYD, INC. Purchase Obligation, to be Paid, after Year Five
INVIVYD, INC. (IVVD) had Purchase Obligation, to be Paid, after Year Five of $6.59 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueAfterFifthYear · last filed 2026-08-13
- 2026-06-30: Purchase Obligation, to be Paid, after Year Five $6.59M.
- 2026-03-31: Purchase Obligation, to be Paid, after Year Five $6.59M.
| Period end | Purchase Obligation, to be Paid, after Year Five |
|---|---|
| 2026-06-30 | $6.59M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $6.59M 10-Q · filed 2026-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |